GlobeNewswire

Tatung Launches IRIS – An AI-Powered Smart Wi-Fi Extender

Share

Quantenna high performance Mesh Wi-Fi rides the waves to new era of smart home applications via voice command

COLOGNE, Germany, June 04, 2019 (GLOBE NEWSWIRE) -- (ANGA COM 2019) -- Quantenna Communications (NASDAQ: QTNA), a global leader and innovator of high performance Wi-Fi solutions, and Tatung Technology Inc. (TTI), a leader in digital IP set-top box solutions for Tier 1 service providers and the IPTV industry, announced today the launch of IRIS SMC-5550 portable smart Mesh Wi-Fi extender. Based on Quantenna’s Spartan architecture, the all-in-one IRIS serves as a Mesh extender, a voice-controlled smart home hub and a Bluetooth speaker. IRIS allows service providers to deliver whole home coverage with superior Wi-Fi performance, while enabling emerging smart home IoT applications.

The number of connected devices for smart home applications is growing exponentially driving the demand for higher Wi-Fi bandwidth, connectivity and performance everywhere in the home. A modern smart home is best served with an Artificial Intelligence based Internet of Things (AIoT) solution built on Wi-Fi, such as IRIS. In addition to Wi-Fi, IRIS supports Z-Wave and a state-of-the-art voice command interface, along with a multi-language capable home interface. By adding IRIS to existing home networks, service providers can deliver more value-added smart home services to end users in a very simple manner. IRIS can communicate with existing connected devices in the home network, and control various smart home products while optimizing Wi-Fi coverage at home. Consumers will benefit from all the convenience of controlling smart devices via simple voice command, including streaming video or music, home security, home automation and more.

Key features of IRIS:

  • Smart Mesh Wi-Fi extender
  • AIoT voice command hub to Wi-Fi, Z-Wave, AWS/Infrared enabled devices with 12 built-in languages
  • Wireless whole-home audio system for stereo surround, party mode and announcement mode when multiple IRIS’ are used
  • 4 microphone arrays, beamforming, far field recognition and noise cancellation
  • VoIP soft phone for hands-free calls
  • Portable Wi-Fi and Bluetooth speaker with built-in battery (optional)
  • Easy integration for customized apps

“Wi-Fi is the backbone of the smart home,” said Luke Dang, CEO at Tatung Technology, Inc. “With Quantenna’s expertise in Wi-Fi, we are proud to introduce IRIS to bring AI smarts into connected homes. As more and more IoT home products come to the market, the AI technology inside IRIS is a game changer and can truly connect everything in a smart home.”  

“We are excited to work with Tatung to bring this great new AIoT product to market,” said David Carroll, senior vice president, Worldwide Sales at Quantenna. “Tatung’s IRIS is a remarkable example of an OEM creating a breakthrough smart home network product and adding tremendous value on top of Quantenna’s award-winning Wi-Fi technology.”

Tatung will showcase its latest AIoT product line, including IRIS, at ANGA COM 2019, June 4-6, 2019.

About Quantenna Communications
Quantenna (NASDAQ: QTNA) is a global leader and innovator of high-performance Wi-Fi solutions. Founded in 2006, Quantenna has demonstrated its leadership in Wi-Fi technologies with many industry firsts. Quantenna continues to innovate with the mission to perfect Wi-Fi by establishing benchmarks for speed, range, efficiency and reliability. Quantenna takes a multidimensional approach, from silicon and system to software, and provides total Wi-Fi solutions. For more information, visit www.Quantenna.com.

About Tatung Technology Inc.
Tatung specializes in providing a total solution for set-top box and digital home networking products. Tatung partners with leading chipset solution providers and adopts the latest technologies to provide innovative products. With a strong software background, Tatung has served Tier 1 telecom operators worldwide, delivering high quality hardware with software integration in the past decade. For more information, please visit: www.tti.tv.

Quantenna Media Contact
Sally Chan
+1 669 209 5659
pr@quantenna.com

Tatung Media Contact

Emily Cheng
+886 918 542 580
Emily_cheng@tti.tv

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6af123f3-ae69-4afa-9bf0-d3b008bc9953

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Oboya får en viktig order i USA20.8.2019 09:31:00 CESTPressemelding

Oboya Horticulture Industries AB (publ) (”Oboya”) har genom sitt helägda dotterbolag Oboya Metal Qingdao Co. Ltd i Qingdao, Kina fått en order från befintlig kund i USA. Ordervärdet uppgår till ca 0,37 MUSD, motsvarande ca 3,59 MSEK. Ordern avser leverans av blomstervagnar och kommer att levereras från september och fram till oktober 2019. Ordervärdet uppgår till 0,37 MUSD, motsvarande ca 3,59 MSEK. Den befintliga kunden är ett av de ledande logistik-, transport- och serviceföretagen inom odlingsindustrin i Nordamerika. Blomstervagnarna kommer att användas för såväl effektiv transport som för exponering av växter eller blommor i butik. "Det är glädjande att det finns fortsatt efterfrågan på Oboyas produkter i USA, trots nuvarande handelskonflikt mellan Kina och USA. Vi kommer att fortsätta att etablera oss på marknaden och därigenom successivt öka våra marknadsandelar globalt på sikt”, säger Robert Wu, VD för Oboya Horticulture Industries AB. Erik Penser Bank AB är Oboyas Certified Adv

Oboya receives an important order in USA20.8.2019 09:31:00 CESTPress release

Oboya Horticulture Industries AB (publ) ("Oboya") has through its wholly owned subsidiary Oboya Metal Qingdao Co. Ltd. in Qingdao, China received an order from an existing customer in the United States. The order value amounted to approximately USD 0.37 million, corresponding to approximately SEK 3.59 million. The order concerns delivery of flower trolleys and will be delivered from September until October 2019. The order value amounts to USD 0.37 million, corresponding to approximately SEK 3.59 million. The existing customer is one of the leading logistics, transport and service companies in the cultivation industry in North America. The flower trolleys will be used for efficient transport as well as for the exposure of plants or flowers in stores. "It is gratifying that there is continued demand for Oboya's products in the US, despite the current trade conflict between China and the US. We will continue to establish ourselves in the market and thereby gradually increase our market sh

Conditions for sale of Riksbank certificates20.8.2019 09:30:00 CESTPress release

AUCTION DATE: AUG 20, 2019 START DATE: AUG 21, 2019 MATURITY DATE: AUG 28, 2019 NOMINAL AMOUNT: 414.0 BLN FIXED RATE: -0.25 % ALL MONETARY POLICY COUNTERPARTIES ARE INVITED TO SUBMIT BIDS TO THE RIKSBANK (08-6966970) BY 10.00 AM ON AUG 20, 2019, AT THE LATEST. CONFIRMATION OF BIDS TO E-MAIL: RBCERT@riksbank.se THE LOWEST ACCEPTED BID VOLUME IS SEK 1 MLN. THE HIGHEST ACCEPTED BID VOLUME IS SEK 414.0 BLN. RESULT OF AUCTION WILL BE PUBLISHED AT 10.15 (CET/CEST) ON AUG 20, 2019. COMPLETE TERMS AND CONDITIONS CAN BE RETRIEVED AT WWW.RIKSBANK.SE

Karolinska Development's portfolio company Forendo Pharma commences Phase 1b study of its drug candidate FOR-621920.8.2019 09:00:00 CESTPressemelding

STOCKHOLM – August 20, 2019. Karolinska Development (Nasdaq Stockholm: KDEV) announces today that its portfolio company Forendo Pharma has initiated dosing in a Phase 1b clinical study with the aim to demonstrate Proof of Mechanism for FOR-6219 – a drug candidate intended for the treatment of endometriosis. Endometriosis is a chronic condition that affects up to 10 per cent of women in reproductive age and causes repeated pain symptoms, infertility and impaired quality of life. Currently available treatments have limitations in efficacy or cause harmful side effects due to estrogen depletion. FOR-6219 is a HSD17B1 inhibitor aiming to reduce estrogen production locally in the endometriosis lesions. In the Phase 1b study, FOR-6219 will be administered to healthy premenopausal women to explore its effect on the endometrium by measuring changes in endometrial thickness and endometrial estrogen levels. In addition to these local effects, systemic hormone levels will be measured. The study w

Karolinska Development's portfolio company Forendo Pharma commences Phase 1b study of its drug candidate FOR-621920.8.2019 09:00:00 CESTPress release

STOCKHOLM – August 20, 2019. Karolinska Development (Nasdaq Stockholm: KDEV) announces today that its portfolio company Forendo Pharma has initiated dosing in a Phase 1b clinical study with the aim to demonstrate Proof of Mechanism for FOR-6219 – a drug candidate intended for the treatment of endometriosis. Endometriosis is a chronic condition that affects up to 10 per cent of women in reproductive age and causes repeated pain symptoms, infertility and impaired quality of life. Currently available treatments have limitations in efficacy or cause harmful side effects due to estrogen depletion. FOR-6219 is a HSD17B1 inhibitor aiming to reduce estrogen production locally in the endometriosis lesions. In the Phase 1b study, FOR-6219 will be administered to healthy premenopausal women to explore its effect on the endometrium by measuring changes in endometrial thickness and endometrial estrogen levels. In addition to these local effects, systemic hormone levels will be measured. The study w

Nexstim reports good initial results on the use of Smartfocus® technology in treatment of major depressive disorder20.8.2019 09:00:00 CESTPress release

Press Release, Helsinki, 20 August 2019 at 10.00 am (EET) Nexstim reports good initial results on the use of Smartfocus ® technology in treatment of major depressive disorder Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") – the company developing and marketing a unique brain stimulation technology for personalized treatment of major depressive disorder (MDD) – announces that the first white paper about the initial experiences of its NBT® system with SmartFocus® technology in treatment of MDD has been published. The white paper is published by Island Psychiatry PC, a New York -based TMS therapy provider and Nexstim. It reports the experiences in the first 10 consecutive patients completing treatment of MDD with Nexstim NBT® system at Island Psychiatry’s clinic. The treatment outcomes of these 10 adult patients were good. 50 % of the patients were in remission at the end of the treatment while 70 % had obtained a clinical response rate. These patient-reported outcomes are hi